Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.54 |
| ▸ | HTR1A | P08908 | 2/20 | 0.52 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6592915 | 0.95 | DRD2 (0.60) | DRD2HTR1A | |
| Oxalic Acid SCHEMBL6784806 | 0.88 | DRD2 (0.54) | DRD2HTR1AADRA1D | |
| Oxalic Acid SCHEMBL6588728 | 0.87 | DRD2 (0.54) | DRD2HTR1AADRA1D | |
| Oxalic Acid SCHEMBL6592488 | 0.84 | DRD2 (0.56) | DRD2HTR1A | |
| SCHEMBL6589502 | 0.82 | DRD2 (0.60) | DRD2HTR1A | |
| SCHEMBL6588661 | 0.81 | DRD2 (0.59) | DRD2HTR1A | |
| SCHEMBL6590561 | 0.81 | DRD2 (0.59) | DRD2HTR1A | |
| Oxalic Acid SCHEMBL6782666 | 0.76 | HTR1A (0.58) | DRD2HTR1A | |
| Oxalic Acid SCHEMBL6772745 | 0.75 | HTR1A (0.52) | HTR1A | |
| SCHEMBL8304293 | 0.74 | DRD2 (0.70) | DRD2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6727263-B2 | SEROTONINE REUPTAKE INHIBITOR; ANTIDEPRESSANTS; SIDE EFFECT REDUCTION | H. LUNDBECK A/S (DK) | 2004-04-27 | — | — | US | disclosed |
| US-20030018050-A1 | Indole and 2,3-dihydroindole derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2003-01-23 | — | — | US | disclosed |
| US-6476035-B1 | Indole and 2,3-dihydroindole derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2002-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018050-A1 | Indole and 2,3-dihydroindole derivatives, their preparation and use | TPH1, HTR1A, HTR3A | DRD2 26/4885HTR1A 2/4885ADRA1D 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.